NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer
NOAC9 - A Phase II Randomised Nordic Anal Cancer Group Study on Circulating Tumor DNA Guided Follow-Up
Aarhus University Hospital
400 participants
Aug 2, 2023
INTERVENTIONAL
Conditions
Summary
This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.
Eligibility
Inclusion Criteria3
- Patients with SCCA eligible for definitive (chemo)radiotherapy
- ≥ 18 of years
- Written and oral consent
Exclusion Criteria3
- Conditions that will contraindicate blood samples
- Conditions that will contraindicate a PET-CT scan.
- Potential lack of compliance to standard FU program and study participation.
Interventions
Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05572801